Provided by Tiger Trade Technology Pte. Ltd.

Crinetics Pharmaceuticals Inc.

41.10
-2.6400-6.04%
Post-market: 41.250.1500+0.36%19:04 EST
Volume:1.57M
Turnover:64.80M
Market Cap:4.30B
PE:-9.05
High:45.18
Open:45.12
Low:40.36
Close:43.74
52wk High:57.99
52wk Low:24.10
Shares:104.71M
Float Shares:96.32M
Volume Ratio:2.09
T/O Rate:1.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5405
EPS(LYR):-3.6939
ROE:-40.17%
ROA:-25.22%
PB:4.34
PE(LYR):-11.13

Loading ...

Stock Track | Crinetics Pharmaceuticals Plummets 5.58% Intraday on Mixed Analyst Ratings

Stock Track
·
Feb 27

Piper Sandler Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
Feb 27

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA)

TIPRANKS
·
Feb 27

Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 27

Earnings Flash (CRNX) Crinetics Pharmaceuticals Posts Q4 Loss $1.29, vs. FactSet Est of $1.35 Loss

MT Newswires Live
·
Feb 27

Crinetics Pharma FY 2025 net loss hits USD 465.3 million, up 55.9%

Reuters
·
Feb 27

BRIEF-Crinetics Pharmaceuticals Q4 Net Income USD -122.815 Million

Reuters
·
Feb 27

Crinetics Pharmaceuticals Q4 Basic EPS USD -1.29

THOMSON REUTERS
·
Feb 27

Earning Preview: Crinetics Pharmaceuticals Inc. this quarter’s revenue is expected to increase by 555%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 19

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Abbott Laboratories (ABT)

TIPRANKS
·
Feb 14

Crinetics Pharmaceuticals Participates in TD Cowen and Leerink Investor Conferences

Reuters
·
Feb 06

Crinetics Pharmaceuticals Inc : Stifel Raises Target Price to $84 From $75

THOMSON REUTERS
·
Jan 30

U.S. RESEARCH ROUNDUP-Definium Therapeutics, Kenvue, Werner Enterprises

Reuters
·
Jan 30

Crinetics Pharmaceuticals Inc. to Report Fourth Quarter and Full Year 2025 Financial Results

Reuters
·
Jan 27

Crinetics Pharmaceuticals Promotes Jeff Knight to Chief Development and Operating Officer

Reuters
·
Jan 26

Crinetics Reports Patient Dosing in Congenital Adrenal Hyperplasia Trial

MT Newswires Live
·
Jan 23

Crinetics doses first patient in BALANCE-CAH trial

TIPRANKS
·
Jan 23

Crinetics Pharmaceuticals Launches Phase 2/3 Pediatric Trial of Atumelnant for Congenital Adrenal Hyperplasia

Reuters
·
Jan 23

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (Cah)

THOMSON REUTERS
·
Jan 23

Crinetics Pharmaceuticals Inc. Publishes Transcript of J.P. Morgan Healthcare Conference Presentation

Reuters
·
Jan 14